Revvity
Kevin Hemphill is an experienced R&D Manager currently leading research and development initiatives at Revvity in the gene editing and modulation sector. Kevin previously held the same title at Horizon Discovery, where innovations in gene editing and modulation technologies were advanced. Kevin also contributed significantly as a Scientist II and Scientist I in Biology R&D roles at Horizon Discovery, focusing on new technologies and CRISPR products. Prior experience includes positions in viral manufacturing at Dharmacon, where Kevin developed standard operating procedures and launched various gene editing products. Kevin's academic background includes a Master’s Degree in Molecular Cellular and Developmental Biology from the University of Colorado Boulder and a Bachelor's Degree in Biochemistry from New Mexico State University.
This person is not in any teams
This person is not in any offices
Revvity
9 followers
At Revvity, “impossible” is inspiration, and ""can't be done"" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With more than $3 billion in revenue and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries. Learn more at www.revvity.com